ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years
Ying‐Nai Wang
Matched on ORCID iD 0000-0002-5275-6729; OpenAlex author ID A5064884375. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 24
2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 3
- All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-026-72271-5↗
- All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer Co-author DOI 10.1101/2024.10.20.619300↗
- Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2018.02.012↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yongkun Wei · 3 shared papers, 2018–2026 · strength 0.42
- Paper All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immuno… DOI 10.1038/s41467-026-72271-5↗
- Paper All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer DOI 10.1101/2024.10.20.619300↗
- Paper Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. DOI 10.1016/j.ccell.2018.02.012↗
- Haoqiang Ying · 3 shared papers, 2018–2026 · strength 0.42
- Paper All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immuno… DOI 10.1038/s41467-026-72271-5↗
- Paper All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer DOI 10.1101/2024.10.20.619300↗
- Paper Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. DOI 10.1016/j.ccell.2018.02.012↗
- Anirban Maitra · 3 shared papers, 2018–2026 · strength 0.42
- Paper All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immuno… DOI 10.1038/s41467-026-72271-5↗
- Paper All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer DOI 10.1101/2024.10.20.619300↗
- Paper Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. DOI 10.1016/j.ccell.2018.02.012↗
- Mien‐Chie Hung · 3 shared papers, 2018–2026 · strength 0.42
- Paper All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immuno… DOI 10.1038/s41467-026-72271-5↗
- Paper All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer DOI 10.1101/2024.10.20.619300↗
- Paper Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. DOI 10.1016/j.ccell.2018.02.012↗
- Ching-Fei Li · 2 shared papers, 2024–2026 · strength 0.37
- Paper All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immuno… DOI 10.1038/s41467-026-72271-5↗
- Paper All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer DOI 10.1101/2024.10.20.619300↗
- Jianhua Ling · 2 shared papers, 2024–2026 · strength 0.37
- Paper All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immuno… DOI 10.1038/s41467-026-72271-5↗
- Paper All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer DOI 10.1101/2024.10.20.619300↗
- Jie Fu · 2 shared papers, 2024–2026 · strength 0.37
- Paper All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immuno… DOI 10.1038/s41467-026-72271-5↗
- Paper All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer DOI 10.1101/2024.10.20.619300↗
- Paul J. Chiao · 2 shared papers, 2024–2026 · strength 0.37
- Paper All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immuno… DOI 10.1038/s41467-026-72271-5↗
- Paper All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer DOI 10.1101/2024.10.20.619300↗
- Li‐Yuan Bai · 2 shared papers, 2024–2026 · strength 0.37
- Paper All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immuno… DOI 10.1038/s41467-026-72271-5↗
- Paper All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer DOI 10.1101/2024.10.20.619300↗
- Dihua Yu · 2 shared papers, 2024–2026 · strength 0.37
- Paper All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immuno… DOI 10.1038/s41467-026-72271-5↗
- Paper All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer DOI 10.1101/2024.10.20.619300↗
- Huamin Wang · 2 shared papers, 2018–2026 · strength 0.26
- Paper All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immuno… DOI 10.1038/s41467-026-72271-5↗
- Paper Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. DOI 10.1016/j.ccell.2018.02.012↗
- Cheng‐Wei Chou · 1 shared paper, 2026 · strength 0.21
- Wantong Yao · 1 shared paper, 2026 · strength 0.21
- Milind M. Javle · 1 shared paper, 2018 · strength 0.06
- Matthew H. G. Katz · 1 shared paper, 2018 · strength 0.06
- Xifeng Wu · 1 shared paper, 2018 · strength 0.06
- Wei‐Jan Wang · 1 shared paper, 2018 · strength 0.06
- Ya’an Kang · 1 shared paper, 2018 · strength 0.06
- Jun Yao · 1 shared paper, 2018 · strength 0.06
- Laura R. Prakash · 1 shared paper, 2018 · strength 0.06
- Jason B. Fleming · 1 shared paper, 2018 · strength 0.06
- Michael P. Kim · 1 shared paper, 2018 · strength 0.06
- David R. Fogelman · 1 shared paper, 2018 · strength 0.06
- Donghui Li · 1 shared paper, 2018 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.